"Insights," "Learnings,"and "Findings" | maslansky + partners
In our work, we often hear “insights,” “learnings,” and “findings” used interchangeably. But are they really the same? And does it matter which one you use?| maslansky+partners
If you’re in pharma communications and you think you’re in the business of “building trust,” you’re already behind. The rules have changed. And the stakes have never been higher. Lee Carter offers a wake-up call for those in pharma comms... and five key shifts to make to resonate with patients today. The post The Stakes Have Never Been Higher: Why Pharma Must Rethink Reputation—Now appeared first on maslansky+partners.| maslansky+partners
The Make America Healthy Again (MAHA) Commission has dropped its roadmap, and while the headlines sound like the usual policy fare (“modernize vaccines,” “expand injury research,” “re-evaluate childhood schedules”), what’s really happening is a communications earthquake. Ignore it, and you do so at your own peril. The post Vaccines, DTC, MAHA, and the Battle for Trust: Why Pharma Can’t Afford to Sit This One Out appeared first on maslansky+partners.| maslansky+partners
In our work, we often hear “insights,” “learnings,” and “findings” used interchangeably. But are they really the same? And does it matter which one you use?| maslansky+partners
The controversy around American Eagle’s "good genes" jeans ad with Sydney Sweeney is not about denim or DNA. Lee Carter explores why the left and the right are so outraged.| maslansky+partners
Chris Foster, CEO of OPRG, joins HearSay to share highlights from new Maslansky + Partners research that examines the state of the world and business today.| maslansky+partners
